Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase <scp>III</scp> trials

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase <scp>III</scp> trials

In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been the standard measure in regulatory outcomes for registration clinical trials in atopic dermatitis (AD), including those supporting the recent approval of dupilumab. To evaluate the treatm...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Jonathan I. Silverberg, Eric L. Simpson, Marius Ardeleanu, Diamant Thaçi, S. Barbarot, Jerry Bagel, Z. Chen, Laurent Eckert, J. Chao, Andrew Korotzer, E. Rizova, Ana B. Rossi, Yuan Lü, NM Graham, Thomas Hultsch, Gianluca Pirozzi, Bolanle Akinlade
Format: Artigo
Jezik:angleščina
Izdano: 2019
Online dostop:https://doi.org/10.1111/bjd.17791
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjd.17791
Oznake: Označite
Brez oznak, prvi označite!

Internet

https://doi.org/10.1111/bjd.17791
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjd.17791

Podobne knjige/članki